After first two initial cycles of 225Ac-PSMA-617 therapy, 68Ga-PSMA PET/CT scan demonstrated a significant reduction in the cancer burden, revealed residual disease in the mediastinal lymph nodes with fluctuating PSA, hence, further 5 cycles were required to achieve complete biochemical, molecular and morphological response. The gene discussed is FOLH1; the disease is cancer.